Inhibrx Biosciences Stock Surges on Positive Phase 2 Cancer Drug Trial Results
Inhibrx Biosciences (INBX) shares skyrocketed more than 60% in premarket trading following promising Phase 2 data for its experimental cancer drug ozekibart. The treatment demonstrated a 52% reduction in disease progression risk for chondrosarcoma patients, a rare bone cancer with limited therapeutic options.
The trial's median progression-free survival more than doubled to 5.52 months compared to placebo, while disease control rates reached 54%. These results position ozekibart as a potential breakthrough for a condition that currently carries a poor prognosis.
Market reaction suggests anticipation of regulatory fast-tracking or partnership opportunities with major pharmaceutical firms. Inhibrx plans to engage the FDA ahead of a planned Biologics License Application submission in 2026.
